Johnson & Johnson says its marketing practices being investigated

Sat Feb 23, 2013 7:29am IST

Stocks

   

(Reuters) - Johnson & Johnson (JNJ.N) said on Friday the U.S. Justice Department is investigating the company's marketing practices related to the hip-replacement product it recalled in 2010 over safety concerns.

The diversified healthcare company has also had to recall over-the-counter drugs, contact lenses, heart devices, such as stents, and insulin pump cartridges over the past couple of years.

In August 2010, J&J recalled two types of its ASR metal-on-metal hip implants after they were linked to high failure rates.

Some 93,000 of the ASR hips were sold prior to the recall, which has generated more than 10,000 lawsuits alleging harm from the devices.

J&J said in a regulatory filing that the government is investigating false claims or false statements affecting federal health care programs in connection with the marketing and use of the ASR XL Hip device.

The company said some of its divisions received an informal request in August 2012 from the U.S. attorney's office in Massachusetts and the Justice Department's civil division seeking materials related to the product, the ASR XL Hip device.

J&J said it has voluntarily produced documents in response to the government's informal requests and is fully cooperating with the government's civil investigation.

(Reporting by Neha Alawadhi in Bangalore; Editing by Jackie Frank)

Monetary Policy Committee

Reuters Showcase

Microfinance

Microfinance

Funding the unfunded: India helps small business borrow to grow  Full Article 

Insurance Sector

Insurance Sector

UK healthcare firm Bupa sees strong growth in India  Full Article 

Sensex Rises

Sensex Rises

Sensex edges up; consumer and healthcare stocks rise  Full Article 

Market Eye

Market Eye

FTSE adds nine Indian firms as large-caps in Asia-Pacific ex-Japan index   Full Article 

Indian Ocean Diplomacy

Indian Ocean Diplomacy

PM Modi to ramp up help for Indian Ocean nations to counter China influence  Full Article 

ECB Bond-Buying

ECB Bond-Buying

ECB raises growth forecasts, to start printing money next week  Full Article 

China Economy

China Economy

China signals "new normal" with lower annual growth target  Full Article 

Pharma Sector

Pharma Sector

Panel recommends waiving late-stage trials for some drugs  Full Article 

E-commerce

E-commerce

China backs e-commerce expansion in win for Alibaba, JD.com  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage